Phase I trials of the oral histone deacetylase (HDAC) inhibitor MGCD0103 given either daily or 3x weekly for 14 days every 3 weeks in patients (pts) with advanced solid tumors
暂无分享,去创建一个
K. Gelmon | A. Tolcher | M. Carducci | L. Siu | A. Kalita | J. Longstreth | Zuomei Li | J. Besterman | G. Reid | V. Callejas